Magrilan

Fluoxetine

Method of action: Antidepressant, Psychoanaleptics, Timoleptic

Treatment option: Bulimia, Bulimia Nervosa, Depression, Neurosis, Obsessive Compulsive Personality Disorder

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Magrilan

What is Magrilan? Defining the Medicine's Identity

Property	Description
Active ingredient	Fluoxetine (as Fluoxetine Hydrochloride)
Form	Capsule, Tablet, Oral Solution (Oral route)
Pharmacological class	Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose	Balancing brain chemistry to support mood
Origin	Synthetic compound

Magrilan: Definition and Pharmacological Classification

Magrilan is a prescription-only medicine that contains the active ingredient Fluoxetine Hydrochloride, classifying it as a Selective Serotonin Reuptake Inhibitor (SSRI). This medicine is a synthetic compound designated as an antidepressant that primarily acts upon the Central Nervous System (CNS). Fluoxetine is clinically recognized as a first-generation SSRI often relied upon to manage persistent low mood, and is noted for its effectiveness in clinical use. This recognition reflects the medication’s established mechanism. The chemical structure of the active agent, Fluoxetine, is established in pharmaceutical documentation.

Composition, Forms, and General Therapeutic Purpose

The drug is a single-ingredient product, administered via the oral route, intended to help balance key brain chemicals associated with mood regulation. The core composition is Fluoxetine Hydrochloride, supplied in several drug forms, including capsules, tablets, and an oral solution. The availability of an oral solution provides flexibility for administration. The primary physiological action involves the potent, highly selective inhibition of serotonin reuptake, a well-characterized mechanism. The general therapeutic purpose is to increase the availability of the monoamine neurotransmitter serotonin, fostering a more stable emotional baseline and promoting a balanced mental state.

What side effects are possible with Magrilan?

Possible Side Effects and Safety Information

The safety profile for Magrilan (Fluoxetine) is based on classifications from governmental regulatory authorities, which group documented adverse reactions by frequency and affected body system. These official classifications establish the risk profile without providing prescriptive guidance.

Frequency and System-Organ Effects

Adverse reactions classified as Very Common (ge 10%) often involve the Nervous System and Gastrointestinal Tract, including headache, nausea, diarrhea, insomnia, and fatigue. Reactions categorized as Common (1% to < 10%) include anxiety, decreased libido, dry mouth, tremor, and sweating. The official records categorize effects across various System-Organ Classes, such as Psychiatric Disorders, Metabolism and Nutrition Disorders (e.g., anorexia), and Cardiac Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory labeling identifies serious adverse reactions requiring explicit safety notification. These include Serotonin Syndrome, which is a potentially life-threatening reaction associated with changes in mental status and neuromuscular function. Other high-risk events documented are QT Prolongation and Ventricular Arrhythmia, and the risk of Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults during the initial phase of treatment or following dose adjustment. Abnormal Bleeding is also a documented risk.

Population and Contextual Safety Notes

Safety constraints apply to specific populations. Patients with hepatic impairment may require a lower or less frequent dosage due to the drug's metabolism. Older adults may have an increased risk of hyponatremia (low sodium levels). The timing of certain effects is noted, such as akathisia (restlessness), which is most likely to occur within the first few weeks of treatment.

Overdose and Emergency Response

Magrilan Overdose and When to Seek Help

This information is based solely on regulatory-documented findings and is not medical advice. Magrilan overdosage is a serious medical event that requires immediate attention.

Documented Overdose Manifestations

Official labeling documents report that overdosage with Magrilan may present with a spectrum of effects affecting the Central Nervous System and Cardiovascular System. Documented signs include specific changes such as CNS depression, confusion, and dizziness. More severe manifestations include the potential for significant changes in vital signs, such as tachycardia or hypotension, and, in rare instances, severe respiratory or cardiac compromise.

When Urgent Medical Help is Required

Per official instructions, urgent medical assistance must be sought upon known or suspected overdosage, regardless of the presence or absence of symptoms. Ingesting amounts significantly exceeding the maximum therapeutic dose is defined as an overdose risk that requires professional intervention.

Overdose Management and Monitoring

Management of Magrilan overdosage is generally supportive and symptomatic, focused on maintaining vital functions. Official instructions advise immediate contact with a certified Poison Control Center or emergency services for specific guidance. Following stabilization, continuous clinical monitoring, including observation of cardiovascular parameters, may be required for a specified period to manage potential delayed or prolonged effects.

Therapeutic Uses of Magrilan

What Magrilan Treats: Main Uses and Benefits

Magrilan (Fluoxetine) is commonly used in clinical settings marked by persistent, distressing emotional and behavioral symptoms. It is applied across multiple domains where additional symptomatic support is needed, generally assisting patients with symptom fluctuations. Clinical applications generally address conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, Premenstrual Dysphoric Disorder (PMDD), and acute depressive episodes associated with Bipolar I Disorder (when used in combination with olanzapine).

The therapeutic support is primarily relevant when symptoms interfere with daily comfort. Magrilan helps address symptom clusters that may become intense, such as persistent sadness and unwanted, intrusive thoughts, or when behavioral patterns escalate, like those seen in Bulimia Nervosa. The medicine may assist patients in coping more steadily with symptom fluctuations and supports managing distressing manifestations, providing supportive relief when symptoms interfere with routine activities.

“This medicine is relevant when supportive symptom management is appropriate across multiple conditions marked by significant symptom expression.”

Quick Fact: Relief for Obsessive-Compulsive Behaviors

Magrilan is considered relevant for easing the symptoms of Obsessive-Compulsive Disorder (OCD), helping to manage the intensity of recurrent, intrusive thoughts and ritualistic behaviors.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Magrilan

Magrilan (Fluoxetine) use is defined by official regulatory criteria that determine who is eligible to use the medicine and who must not use it. These rules are established by authorities such as the FDA and EMA.

Eligibility Domain	Official Regulatory Status
Absolute Contraindications	Prohibited in patients with known hypersensitivity to Fluoxetine and those taking Monoamine Oxidase Inhibitors (MAOIs), Pimozide, or Thioridazine [FDA Label: 4]. Use is also contraindicated in Severe Renal Failure (GFR < 10 mL/min) or Unstable Epilepsy [EMA SmPC].
Age-Group Eligibility	Allowed for Adults (18+). For Major Depressive Disorder, use is approved for children aged 8 to 18 years; for Obsessive-Compulsive Disorder, the minimum age is 7 years [FDA Label: 8.4]. Use is not established for children below these thresholds.
Organ Function Status	Conditional Use: A lower or less frequent dosage must be considered for patients with severe hepatic impairment (cirrhosis) due to the drug's prolonged half-life [FDA Label: 8.6]. Caution is advised for older adults with concurrent disease [FDA Label: 8.5].
Pregnancy and Lactation	Restricted/Not Recommended: Use should be avoided during pregnancy, particularly the third trimester. Breastfeeding is not recommended as the compound and its metabolite are excreted in human milk [FDA Label: 8.1, 8.3].

The regulatory profile clearly defines population restrictions to ensure use remains within established safety parameters, specifically prohibiting use with conflicting medications and limiting use based on age, organ function, and reproductive status.

What should I know about interactions with other medicines?

Magrilan (Fluoxetine) has officially documented interaction patterns that are classified based on the potential for pharmacokinetic changes and adverse pharmacodynamic effects, primarily stemming from its established role as a potent inhibitor of the metabolic enzyme CYP2D6.

Contraindicated Combinations

Co-administration with certain agents is strictly prohibited by regulatory labeling. These include Monoamine Oxidase Inhibitors (MAOIs), such as Linezolid and intravenous Methylene Blue, due to the documented high risk of Serotonin Syndrome. The medicine is also contraindicated with Pimozide and Thioridazine due to the risk of QTc prolongation and elevated plasma concentrations of the co-administered drug.

Pharmacokinetic and Pharmacodynamic Interactions

As a potent CYP2D6 inhibitor, Magrilan may lead to elevated plasma concentrations and increased exposure of other medicines metabolized by this enzyme, including Tricyclic Antidepressants (TCAs), certain Antipsychotics, and Anticonvulsants (e.g., Phenytoin). Co-administration with other serotonergic agents (e.g., Triptans, Lithium) or non-medicinal products like the herbal supplement St. John's Wort or Tryptophan carries a documented risk of Serotonin Syndrome. Additionally, concomitant use with drugs that interfere with hemostasis (e.g., NSAIDs, Warfarin) may potentiate the documented risk of bleeding.

Timing and Separation Requirements

Mandatory separation periods are required when switching treatments. Magrilan must not be started until at least 14 days after stopping an MAOI, and an MAOI or Thioridazine must not be started until at least 5 weeks after stopping Magrilan. The label also advises avoiding alcohol consumption.

Mechanism of Action

How Magrilan Works

Magrilan (Fluoxetine) acts by influencing molecular and cellular mechanisms within the Central Nervous System (CNS) through a sequence of time-dependent actions, involving both immediate interactions with transporters and long-term effects on neuronal architecture.

Synaptic Serotonin Enhancement

The foundational action involves binding to and inhibiting the Serotonin Transporter (SERT) protein. This targeted blockade prevents the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron. This results in an immediate and measurable rise in the extracellular concentration of 5-HT available for signaling. The active metabolite, Norfluoxetine, contributes to this mechanism, resulting in a sustained and prolonged physiological activity of the transporter inhibition.

Neurotrophic Signaling and Neuronal Plasticity

The full physiological effect requires a prolonged cascade beyond the immediate serotonin increase. Over time, the sustained presence of 5-HT triggers the desensitization of autoreceptors and the modulation of the Brain-Derived Neurotrophic Factor (BDNF) pathway. This action involves neuronal plasticity and remodeling through enhanced neurogenesis and synaptogenesis in key brain areas. These are the fundamental biological changes that lead to an altered and sustained physiological activity within the CNS.

Dosage and Administration Information

How to Use Magrilan

Magrilan (Fluoxetine) administration is governed by a precise set of instructions defining its route, dosage, frequency, and population-specific considerations. The medicine is exclusively administered via the oral route across all authorized forms, including immediate-release capsules, tablets, and oral solution.

Dosing and Frequency Patterns

The standard regimen for most adult uses, such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), starts at 20 mg once daily in the morning. The typical maintenance dose ranges from 20 mg to 60 mg daily, with a maximum dose of 80 mg per day. For Bulimia Nervosa, the fixed authorized dose is 60 mg once daily.

Administration Detail	Official Requirement
Standard Intake	Taken orally, with or without food.
Adjustment Timeline	Dose adjustments are typically considered only after several weeks of treatment.
Weekly Dosing	A 90 mg delayed-release capsule is authorized for once-weekly dosing in certain maintenance treatments, and must be swallowed whole.

Population-Specific Adjustments

Standard protocols require specific dosing modifications for certain groups. For older adults and individuals with hepatic impairment, a lower or less frequent dosing schedule (e.g., alternate-day dosing) is recommended due to potential clearance issues. For pediatric patients with MDD or OCD, the standard starting dose is 10 mg once daily.

The official usage protocol defines the specific route, quantity, and timing of Magrilan intake, strictly separating administration logistics from any clinical outcome or safety guidance.

Recent Clinical Evidence

Magrilan: Recent Clinical Evidence

Research on Magrilan (Fluoxetine) relies primarily on studies conducted under controlled conditions, such as Randomized Controlled Trials (RCTs), which compare the medicine against a placebo over defined periods. This section outlines the types of studies conducted, the outcomes measured, and the recognized research limitations.

Evidence for Core Indications (MDD, OCD, Bulimia Nervosa, Panic Disorder)

For Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), numerous short-term RCTs evaluated measured change in standardized symptom scores in adult and pediatric subjects. Maintenance trials tracked subjects for longer follow-up periods, and research reported on the proportion of subjects who met criteria for a defined response. Data for OCD indicated patterns related to measured change in outcomes capturing heightened symptom activity.

For Bulimia Nervosa, studies monitored specific behavioral outcomes, such as the frequency of binge-eating episodes, over acute phases typically lasting 8 to 16 weeks. Research describes patterns of change observed in measured behavioral frequency. For Panic Disorder, research explored outcomes related to the frequency of panic attacks over approximately 12 weeks, and studies monitored functional impairment throughout these trials.

Evidence in Specific Populations and Research Gaps

Magrilan was evaluated in specific groups, including pediatric patients for MDD and OCD. The evidence quality varies across studies for the pediatric MDD population, and some analyses indicate that the results were inconsistent when compared to adult trials. It was also studied for Bipolar I depressive episodes, but only as a combination treatment.

Key limitations across the research landscape include the short duration of most regulatory trials and subsequent limited information for long-term outcomes. This means that while research contributes to understanding short-term changes, unanswered questions remain concerning the long-term management role.

Frequently Asked Questions (FAQ)

Common questions about Magrilan (FAQ)

Q: Is Magrilan a controlled substance?

Magrilan is classified as a Schedule IV controlled substance. This classification indicates that the medication has a potential for dependence and abuse. Due to this risk, patients should take the medication only as prescribed by their healthcare provider. Sharing prescription medication is not recommended.

Q: Can I take Magrilan if I am pregnant or breastfeeding?

Magrilan is generally not recommended for use during pregnancy, as official labeling suggests a risk of harm to the fetus. Data suggests the drug passes into breast milk. A healthcare provider can assess the potential risk to the infant and discuss alternative options, if needed. Discuss any risks or concerns with an OB-GYN or other qualified healthcare professional.

Q: How long does it take for Magrilan to work?

Magrilan may start to have an effect within 30 to 60 minutes of taking a dose. Maximum or full effects may be observed after approximately two weeks of continuous use, according to clinical data. Tracking symptoms can be a way for patients and their doctors to evaluate the medication's effectiveness.

Q: Can I drink alcohol while taking Magrilan?

The product label advises against consuming alcohol while taking Magrilan. Combining this medication with alcohol can increase central nervous system depression, which may lead to extreme drowsiness, respiratory failure, including the potential for severe respiratory depression and, in rare instances, death. This is considered a serious and potentially life-threatening interaction.

How should Magrilan be stored and disposed of?

How to Store and Dispose of Magrilan

Magrilan (Fluoxetine) storage must comply with regulatory requirements to ensure product integrity and safety.

Official Storage Conditions

The medicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). Storage areas must protect the product from light and moisture. The official labeling mandates that the container be kept tightly closed and that the product be dispensed with a child-resistant closure. Magrilan must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Magrilan should primarily be discarded through an official drug take-back program. As Fluoxetine is not on the FDA's flush list, if a take-back option is unavailable, the product must be mixed with an undesirable material, such as dirt or used coffee grounds, sealed, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.